{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:10:54Z","timestamp":1765289454803,"version":"3.46.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:45:54Z","timestamp":1762206354000},"page":"77-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Should Gleason 6 Still Be Considered Cancer? A Narrative Review of its Biology and Clinical Course, with Implications for Guideline Recommendations and Practice Implementation"],"prefix":"10.1016","volume":"53","author":[{"given":"Bowen","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Wilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ucl.2025.09.005_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2021.11.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT","volume":"81","author":"Wilt","year":"2022","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.005_bib27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2025.09.005_bib33","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","article-title":"S-O A. natural history of early, localized prostate cancer","volume":"291","author":"Johansson","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.005_bib35","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2025.09.005_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1073580","article-title":"Gleason 6 prostate cancer: that which cannot be named","volume":"12","author":"Burke","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.005_bib5","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.005_bib6","first-page":"751","article-title":"Treatment of prostatic cancer: studies by the veterans administration cooperative urological research group","volume":"48","author":"Byar","year":"1972","journal-title":"Bull N Y Acad Med"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.005_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2018.09.009","article-title":"The history of urology at the Minneapolis veterans affairs health care system","volume":"123","author":"Lane","year":"2019","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.005_bib9","first-page":"1228","article-title":"The 2005 international Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005"},{"issue":"9663","key":"10.1016\/j.ucl.2025.09.005_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(09)60191-4","article-title":"Donald F gleason","volume":"373","author":"Snyder","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0090-4295(03)00243-7","article-title":"Whitmoreisms: memorable quotes from Willet F. Whitmore, Jr, M.D","volume":"63","author":"Montie","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.005_bib11","first-page":"244","article-title":"The 2014 international Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading","volume":"40","author":"Epstein","year":"2016"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.005_bib12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jama.2013.108415","article-title":"Overdiagnosis and overtreatment in cancer: an opportunity for improvement","volume":"310","author":"Esserman","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.005_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bju.12671","article-title":"Gleason inflation 1998-2011: a registry study of 97,168 men","volume":"115","author":"Danneman","year":"2015","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.005_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"issue":"10071","key":"10.1016\/j.ucl.2025.09.005_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ucl.2025.09.005_bib16","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.005_bib17","first-page":"627","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"71","author":"Loeb","year":"2017","journal-title":"Eur Urol"},{"issue":"S1","key":"10.1016\/j.ucl.2025.09.005_bib18","first-page":"61","article-title":"Gleason grading and prognostic factors in carcinoma of the prostate","volume":"25","author":"Humphrey","year":"2012","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.005_bib19","first-page":"935","article-title":"PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large prostatectomy cohort","volume":"27","author":"Lotan","year":"2014","journal-title":"Mod Pathol"},{"issue":"1623","key":"10.1016\/j.ucl.2025.09.005_bib20","article-title":"Monoallelic expression of TMPRSS2\/ERG in prostate cancer stem cells","volume":"4","author":"Polson","year":"2013","journal-title":"Nat Commun"},{"issue":"5748","key":"10.1016\/j.ucl.2025.09.005_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"7637","key":"10.1016\/j.ucl.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.005_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.005_bib24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.005_bib25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0090-4295(90)80184-O","article-title":"Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer A fifteen-year follow-up","volume":"36","author":"Graversen","year":"1990","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.005_bib32","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.ucl.2025.09.005_bib34","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa043739","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"352","author":"Bill-Axelson","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.005_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.005_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ucl.2025.09.005_bib38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.005_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.005_bib40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.005_bib41","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","article-title":"Long-term outcomes of active surveillance for prostate cancer: the memorial sloan kettering cancer center experience","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.005_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euros.2022.01.008","article-title":"Association between a 22-feature genomic classifier and biopsy gleason upgrade during active surveillance for prostate cancer","volume":"37","author":"Press","year":"2022","journal-title":"European Urology Open Science"},{"issue":"14","key":"10.1016\/j.ucl.2025.09.005_bib29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.19.02267","article-title":"17-gene genomic prostate score test results in the canary prostate active surveillance study (PASS) cohort","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.005_bib30","doi-asserted-by":"crossref","unstructured":"Shee K, Song JJ, Cowan JE, et al. The natural history of confirmed grade group 1 prostate cancer managed with active surveillance in the modern era. Eur Urol Oncol 2025:S2588-9311(25)00177-4. doi:10.1016\/j.euo.2025.06.005.","DOI":"10.1016\/j.euo.2025.06.005"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.005_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"14","key":"10.1016\/j.ucl.2025.09.005_bib42","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1110307","article-title":"Suicide and cardiovascular death after a cancer diagnosis","volume":"366","author":"Fang","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ucl.2025.09.005_bib43","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.33621","article-title":"It\u2019s all in the name: does nomenclature for indolent prostate cancer impact management and anxiety?","volume":"127","author":"Hudnall","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.005_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae087","article-title":"Risk of anxiety disorders in men with prostate cancer: a national cohort study","volume":"8","author":"Crump","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.005_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2024.5994","article-title":"Overtreatment of prostate cancer among men with limited longevity in the active surveillance era","volume":"185","author":"Daskivich","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.005_bib46","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.23502","article-title":"Active surveillance for the management of prostate cancer in a contemporary cohort","volume":"112","author":"Dall\u2019Era","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.005_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085947","article-title":"Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experiments","volume":"14","author":"Bullen","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.ucl.2025.09.005_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euros.2020.11.004","article-title":"Real-world evidence to estimate prostate cancer costs for first-line treatment or active surveillance","volume":"23","author":"Magnani","year":"2021","journal-title":"European urology open science"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.005_bib49","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamaoncol.2016.0386","article-title":"Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors","volume":"2","author":"Nikiforov","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.005_bib50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urolonc.2022.09.028","article-title":"Should grade group 1 prostate cancer be reclassified as \u201cnon-cancer\u201d? A pathology community perspective","volume":"41","author":"Zhou","year":"2023","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.005_bib51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 world Health Organization classification of tumors of the urinary system and Male genital organs\u2014Part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.005_bib52","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Network","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.005_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MOU.0000000000000945","article-title":"Is grade group 1 (gleason score 3 + 3 = 6) adenocarcinoma of the prostate really cancer?","volume":"32","author":"Epstein","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.005_bib54","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","article-title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study","volume":"25","author":"Saha","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.005_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae079","article-title":"Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits","volume":"8","author":"Kwon","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"24","key":"10.1016\/j.ucl.2025.09.005_bib56","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/jnci\/djq417","article-title":"Reduction in physician reimbursement and use of hormone therapy in prostate cancer","volume":"102","author":"Elliott","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.005_bib57","article-title":"The LUGPA alternative payment model for initial therapy of newly diagnosed patients with organ-confined prostate cancer: rationale and development","volume":"19","author":"Kapoor","year":"2017","journal-title":"Rev Urol"},{"key":"10.1016\/j.ucl.2025.09.005_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.02.004","article-title":"An online treatment decision aid for men with low-risk prostate cancer eligible for active surveillance and their partners increases the uptake of active surveillance: the navigate randomised controlled trial","author":"Schofield","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.005_bib59","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/cncr.35190","article-title":"Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: the treatment options in prostate cancer study (TOPCS","volume":"130","author":"Xu","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2025.09.005_bib61","unstructured":"Urology EA. EAU Guidelines. Presented at the EAU Annual Congress Madrid 2025. EAU Guidelines Office; Arnhem, The Netherlands."},{"key":"10.1016\/j.ucl.2025.09.005_bib62","article-title":"Comparing active surveillance and watchful waiting with radical treatment using machine learning models among patients with prostate cancer","volume":"7","author":"Hu","year":"2023","journal-title":"JCO Clin Cancer Inform"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:05:57Z","timestamp":1765289157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0094014325000886"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should Gleason 6 Still Be Considered Cancer? A Narrative Review of its Biology and Clinical Course, with Implications for Guideline Recommendations and Practice Implementation","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}